Ken Itrato
Overview
Ken Itrato is a valued and experienced advisor to his clients in addressing a wide range of transactional, financing, and strategic business issues.
He handles a wide range of strategic and funding transactions, including venture capital, private equity, angel financing, and debt and also has a strong mergers and acquisitions practice. As a trusted team member, Ken advises clients with respect to the legal implications of their day-to-day operations, from complex customer and supplier relationships to employment and equity compensation. He effectively counsels on mission-critical licensing and partnering transactions involving core assets, technologies and/or products.
Career & Education
- General corporate and transactional law, AmLaw 50 firmGeneral corporate and transactional law, AmLaw 200 firm
- Cornell University, B.A.
- Georgetown University Law Center, J.D., Order of the Coif
- Massachusetts
Ken's Insights
Firm News | 2 min read | 05.22.26
May 22, 2026: A Crowell & Moring team represented Kanders & Company in a complex carveout transaction in which Kanders acquired the biosecurity business of publicly traded Ginkgo Bioworks. The resulting company, Perimeter Systems, has launched as the world’s first integrated biosecurity infrastructure platform, designed to transform biological signals into real-time intelligence and accelerate decisive response. At closing, Perimeter secured $60 million in growth capital, led by Kanders in partnership with SCS Financial, Goldcrest Capital, Four Cities Capital, and the Safe Artificial Intelligence Fund (SAIF).
Press Coverage | 09.23.25
Event | 09.18.25
Press Coverage | 08.26.25
Representative Matters
Ken's professional experience encompasses a range of representative matters during his tenure at Faber Daeufer & Itrato PC, prior to his transition to Crowell Life Sciences in 2025. Representative matters include:
- A 25+ year history of equity financings of life sciences organizations including therapeutics companies, biopharmaceutical companies, biotechnology companies, technology companies, and energy companies.
- A 25+ year history of investor-side equity financings on behalf of therapeutics companies, biopharmaceutical companies, biotechnology companies, and technology companies.
- Numerous investments from various venture capital firms and family offices into undisclosed portfolio companies.
- Numerous project financings by private investors on behalf of various companies, and clients by Silicon Valley Bank.
- Numerous strategic transactions, including advising biopharmaceutical, biotechnology, and technology clients across private and public acquisitions, sales or options.
Ken's Insights
Firm News | 2 min read | 05.22.26
May 22, 2026: A Crowell & Moring team represented Kanders & Company in a complex carveout transaction in which Kanders acquired the biosecurity business of publicly traded Ginkgo Bioworks. The resulting company, Perimeter Systems, has launched as the world’s first integrated biosecurity infrastructure platform, designed to transform biological signals into real-time intelligence and accelerate decisive response. At closing, Perimeter secured $60 million in growth capital, led by Kanders in partnership with SCS Financial, Goldcrest Capital, Four Cities Capital, and the Safe Artificial Intelligence Fund (SAIF).
Press Coverage | 09.23.25
Event | 09.18.25
Press Coverage | 08.26.25
Insights
Ken's Insights
Firm News | 2 min read | 05.22.26
May 22, 2026: A Crowell & Moring team represented Kanders & Company in a complex carveout transaction in which Kanders acquired the biosecurity business of publicly traded Ginkgo Bioworks. The resulting company, Perimeter Systems, has launched as the world’s first integrated biosecurity infrastructure platform, designed to transform biological signals into real-time intelligence and accelerate decisive response. At closing, Perimeter secured $60 million in growth capital, led by Kanders in partnership with SCS Financial, Goldcrest Capital, Four Cities Capital, and the Safe Artificial Intelligence Fund (SAIF).
Press Coverage | 09.23.25
Event | 09.18.25
Press Coverage | 08.26.25



